论文部分内容阅读
目的:观察清胰汤联合生长抑素治疗急性胰腺炎的临床疗效。方法:回顾分析2014年1月~2015年6月期间在我院接受治疗的108例急性胰腺炎患者临床资料,将其随机分为对照组和治疗组,每组54例患者。对照组患者给予生长抑素治疗,治疗组患者在对照组治疗的基础上同期加服清胰汤治疗,治疗2个疗程(1个疗程8d),第12天评价两组患者的临床疗效。结果:治疗组患者临床治疗总有效率92.59%,与对照组患者临床治疗总有效率74.07%对比,差异具有统计学意义;治疗结束后临床腹痛、腹胀、压痛症状消失时间以及住院时间明显短于对照组;2组患者血清因子(肿瘤坏死因子、白介素-15)及C反应蛋白(CRP)均明显降低,与对照组对比差异具有统计学意义;治疗组治疗3d、7d、15d后患者血清内毒素水平恢复明显优于对照组;2组患者血、尿淀粉酶均明显降低,且与对照组对比差异具有统计学意义;治疗后2组患者机体细胞因子IL-6、IL-8水平均明显下降,且与对照组对比差异具有统计学意义;在治疗和观察期间,对照组出现10例不良反应,不良反应率为18.51%,治疗组出现3例不良反应,不良反应率为5.55%,与对照组对比差异具有统计学意义。结论:治疗急性胰腺炎采用生长抑素和清胰汤联合治疗,临床效果确切,患者临床症状明显改善,治愈率较高。
Objective: To observe the clinical efficacy of Qingyi Decoction combined with somatostatin in the treatment of acute pancreatitis. Methods: The clinical data of 108 patients with acute pancreatitis treated in our hospital from January 2014 to June 2015 were retrospectively analyzed. They were randomly divided into control group and treatment group, 54 patients in each group. Patients in the control group were treated with somatostatin. Patients in the treatment group were treated with Qingyitang over the same period, two courses of treatment (one course of treatment for 8 days), and the other two groups of patients were evaluated on the 12th day. Results: The total effective rate of clinical treatment in the treatment group was 92.59%, which was significantly higher than that of the control group (74.07%). The difference of clinical abdominal pain, abdominal distension, disappearance of tenderness and hospitalization was significantly shorter than that of the control group The serum levels of TNF-α, IL-15 and CRP in the two groups were significantly lower than those in the control group (P <0.05). The differences between the two groups were statistically significant The levels of IL-6 and IL-8 in the two groups were significantly higher than those in the control group. The levels of blood and urine amylase in the two groups were significantly lower than those in the control group And there were statistically significant differences compared with the control group. During the treatment and observation period, there were 10 adverse reactions in the control group, the adverse reaction rate was 18.51%, the treatment group had 3 adverse reactions, the adverse reaction rate was 5.55%, and The difference between the control group was statistically significant. Conclusion: The treatment of acute pancreatitis with somatostatin and Qingyitang combined treatment, the clinical effect is definite, the clinical symptoms of patients improved significantly, the cure rate is higher.